Vascular Technology, INC.

Reporting payments is a legal requirement; large totals often reflect large product portfolios.

$1.4Mgeneral payments (2019-2025)
$0.00research payments (2019-2025)
58clinicians paid

General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.

General payments by year

2019 $57K
2020 $53K
2021 $55K
2022 $28K
2023 $103K
2024 $943K
2025 $135K

General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.

Specialties it works with most

Urology $1.2M
Plastic Surgery $44K
Colon & Rectal Surgery $37K
Surgery $21K
Gastroenterology (Internal Medicine) $19K
Vascular Surgery $16K

Clinicians with the largest reported totals

Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.

ClinicianLocationSpecialtyGeneral payments (2019-2025)
Michael Stifelman Hackensack, NJ Urology $857,733.59
Jihad Kaouk Cleveland, OH Urology $161,400.00
Ronney Abaza Worthington, OH Urology $149,900.00
John Marks Wynnewood, PA Colon & Rectal Surgery $35,000.00
Mutahar Ahmed Maywood, NJ Urology $27,230.00
Keith Paige Seattle, WA Plastic Surgery $27,000.00
Ihya Gorgun Cleveland, OH Surgery $21,000.00
John Nigriny Lebanon, NH Plastic Surgery $16,125.00
Richard Wong Cleveland, OH Gastroenterology (Internal Medicine) $11,899.00
Garni Barkhoudarian Santa Monica, CA Neurological Surgery $10,750.00

Share this page

Company

Vascular Technology, INC.

$1,373,275.88

general payments reported (2019-2025)

Clinicians paid
58
Research payments
$0.00

https://glasscript.com/company/vascular-technology-inc

Source: CMS Open Payments, 2019-2025. Reporting payments is a legal requirement; large totals often reflect large product portfolios.

Download CSV

The CSV has this whole record: yearly general payments, research totals, product associations, the specialty mix, and the largest reported clinician totals.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.